HealthQuill Chronic Obstructive Pulmonary Disease
Merck & Co. will acquire UK-based Verona Pharma Plc for about $10 billion to gain access to a respiratory drug approved by the US regulator, according to a statement from Merck.
Drugs Health Pharma

Merck to acquire Verona Pharma for $10 billion to net respiratory drug 

HQ Team July 9, 2025: Merck & Co. will acquire UK-based Verona Pharma Plc for about $10 billion and gain access to a.

Read More
The Food and Drug Administration has cleared GSK Plc’s drug for treating patients with inadequately controlled chronic obstructive pulmonary disease (COPD).
Drugs Medical Pharma

GSK Plc’s drug to treat COPD gets clearance from US drug regulator

HQ Team May 24, 2025: The Food and Drug Administration has cleared GSK Plc’s drug for treating patients with inadequately controlled chronic obstructive.

Read More
Sanofi S.A.’s drug, at its highest dose, has failed to meet its targeted reduction in the yearly rate of worsening episodes in adults with moderate-to-severe asthma, according to a statement.
Drugs Health Pharma

Sanofi’s test drug to treat moderate-to-severe asthma fails to meet goals 

HQ Team April 17, 2025: Sanofi S.A.’s drug, at its highest dose, has failed to meet its targeted reduction in the yearly rate.

Read More
Regeneron Pharmaceuticals and Sanofi’s drug, Dupixent, got the US regulator’s approval to treat patients with chronic obstructive pulmonary disease.
Drugs Health Pharma

Regeneron-Sanofi’s drug for lung disease gets US approval

Regeneron Pharmaceuticals and Sanofi’s drug, Dupixent, got the US regulator’s approval to treat patients with chronic obstructive pulmonary disease.

Read More